Selective CD4<sup>+</sup> Lymphopenia in Melanoma Patients Treated With Temozolomide: A Toxicity With Therapeutic Implications
Y.B. Su(Memorial Sloan Kettering Cancer Center), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Philip O. Livingston(Memorial Sloan Kettering Cancer Center), Susan E. Krown(Memorial Sloan Kettering Cancer Center), Theresa Foster(Memorial Sloan Kettering Cancer Center), SeJean Sohn(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), Kent A. Sepkowitz(Memorial Sloan Kettering Cancer Center), Linda Williams(Edinburgh Cancer Research), Carolyn Quinn(Memorial Sloan Kettering Cancer Center)
Cited by 258
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k